Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
ARCAGY/ GINECO GROUP
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07637851CT.gov Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer | — | Not Yet Recruiting | — | — | — |
NCT07564141CT.gov Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer | — | Not Yet Recruiting | — | — | — |
NCT07591831CT.gov Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer | — | Not Yet Recruiting | — | — | — |
NCT07225270CT.gov Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy | — | Recruiting | — | — | — |
NCT07470853CT.gov A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. | — | Recruiting | — | — | — |
NCT07370818CT.gov To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer | — | Not Yet Recruiting | — | — | — |
NCT07340164CT.gov Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy | — | Recruiting | — | — | — |
NCT07318558CT.gov A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) | — | Recruiting | — | — | — |
NCT06971744CT.gov Autophagy Maintenance (AUTOMAIN) | — | Recruiting | — | — | — |
NCT07278336CT.gov A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer | — | Recruiting | — | — | — |
Show 73 more trialsShow fewer
NCT07059845CT.gov A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer | — | Recruiting | — | — | — |
NCT07146919CT.gov AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer | — | Withdrawn | — | — | — |
NCT07120451CT.gov Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker | — | Not Yet Recruiting | — | — | — |
NCT07117877CT.gov Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer | — | Not Yet Recruiting | — | — | — |
NCT07024784CT.gov A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies | — | Recruiting | — | — | — |
NCT06990516CT.gov SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer | — | Not Yet Recruiting | — | — | — |
NCT06787612CT.gov Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer | — | Recruiting | — | — | — |
NCT06954584CT.gov Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer | — | Recruiting | — | — | — |
NCT06769425CT.gov HS-10502 Combination Treatment in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06843447CT.gov A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) | — | Recruiting | — | — | — |
NCT06824467CT.gov A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) | — | Recruiting | — | — | — |
NCT06819007CT.gov Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) | — | Recruiting | — | — | — |
NCT06840002CT.gov A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer | — | Recruiting | — | — | — |
NCT06580314CT.gov Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | — | Recruiting | — | — | — |
NCT06735326CT.gov Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer | — | Recruiting | — | — | — |
NCT06650709CT.gov NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study | — | Not Yet Recruiting | — | — | — |
NCT06377267CT.gov Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial) | — | Unknown | — | — | — |
NCT06083844CT.gov Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy | — | Recruiting | — | — | — |
NCT06063070CT.gov First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer | — | Not Yet Recruiting | — | — | — |
NCT05636111CT.gov Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer | — | Recruiting | — | — | — |
NCT05797168CT.gov Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors | — | Recruiting | — | — | — |
NCT05824975CT.gov A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | — | Recruiting | — | — | — |
NCT05445778CT.gov Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | — | Active Not Recruiting | — | — | — |
NCT05065021CT.gov Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor | — | Unknown | — | — | — |
NCT06307249CT.gov Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA | — | Recruiting | — | — | — |
NCT05739981CT.gov Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer | — | Recruiting | — | — | — |
NCT05238831CT.gov SMMART Adaptive Clinical Treatment (ACT) Trial | — | Withdrawn | — | — | — |
NCT05431582CT.gov Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors | — | Withdrawn | — | — | — |
NCT05579366CT.gov Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | — | Recruiting | — | — | — |
NCT05009082CT.gov Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer | — | Recruiting | — | — | — |
NCT05489211CT.gov Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | — | Recruiting | — | — | — |
NCT05453825CT.gov A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors | — | Unknown | — | — | — |
NCT05044871CT.gov Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer | — | Completed | — | — | — |
NCT05200260CT.gov Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer | — | Recruiting | — | — | — |
NCT05200364CT.gov A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer | — | Terminated | — | — | — |
NCT05170594CT.gov A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer | — | Unknown | — | — | — |
NCT05116189CT.gov Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). | — | Active Not Recruiting | — | — | — |
NCT04847063CT.gov Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies | — | Recruiting | — | — | — |
NCT04931342CT.gov A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | — | Active Not Recruiting | — | — | — |
NCT05039801CT.gov IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04731467CT.gov A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | — | Completed | — | — | — |
NCT04938583CT.gov Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT04657068CT.gov A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT04679064CT.gov Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment | — | Unknown | — | — | — |
NCT03806049CT.gov Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer | — | Withdrawn | — | — | — |
NCT03872947CT.gov A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03737643CT.gov Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients | — | Active Not Recruiting | — | — | — |
NCT03740165CT.gov Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) | — | Completed | — | — | — |
NCT03596281CT.gov Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer | — | Completed | — | — | — |
NCT03363867CT.gov BEACON - ABC in Recurrent Platinum Resistant HGSOC | — | Unknown | — | — | — |
NCT03394885CT.gov Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer | — | Completed | — | — | — |
NCT03604653CT.gov Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers | — | Completed | — | — | — |
NCT03197584CT.gov QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy | — | Withdrawn | — | — | — |
NCT03367182CT.gov Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer | — | Completed | — | — | — |
NCT03038100CT.gov A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | — | Completed | — | — | — |
NCT02873962CT.gov A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib | — | Active Not Recruiting | — | — | — |
NCT02661815CT.gov A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer | — | Terminated | — | — | — |
NCT02399592CT.gov Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer | — | Completed | — | — | — |
NCT02354131CT.gov Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer | — | Completed | — | — | — |
NCT02142803CT.gov TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02121990CT.gov Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | — | Completed | — | — | — |
NCT02033551CT.gov A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors | — | Completed | — | — | — |
NCT01802749CT.gov Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer | — | Unknown | — | — | — |
NCT01551745CT.gov Salvage Ovarian FANG™ Vaccine + Bevacizumab | — | Completed | — | — | — |
NCT01838538CT.gov Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy | — | Unknown | — | — | — |
NCT01248949CT.gov A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01031381CT.gov Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer | — | Completed | — | — | — |
NCT01821859CT.gov Abraxane/Bevacizumab | — | Terminated | — | — | — |
NCT00976911CT.gov AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | — | Completed | — | — | — |
NCT00989651CT.gov Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | — | Completed | — | — | — |
NCT01010126CT.gov Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | — | Completed | — | — | — |
NCT00959647CT.gov A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study | — | Completed | — | — | — |
NCT00910000CT.gov Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Irinotecan (this asset) | ARCAGY/ GINECO GROUP | Approved | BB · 67 |
| Tisotumab Vedotin | Seagen Inc. | P2 | BB |
| TIL | Inge Marie Svane | P2 | BB |
| Olaparib | Shandong University | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | Kalinski, Pawel, MD, PhD | P3 | BB |
| Adriamycin | Genmab | P3 | BB |
| Carboplatin | Fudan University | P4 | BB |
| OTL-38 | On Target Laboratories, LLC | P4 | BB |
| Nogitecan | Genmab | P3 | BB |
+42 more in the Ovarian Cancer cohort
Other indications for Irinotecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Cancer | — | P4 | BBB · 78 |
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Irinotecan in Ovarian Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/irinotecan-ovarian-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →